1
|
Scionti I, Hayashi S, Mouradian S, Girard E, Esteves de Lima J, Morel V, Simonet T, Wurmser M, Maire P, Ancelin K, Metzger E, Schüle R, Goillot E, Relaix F, Schaeffer L. LSD1 Controls Timely MyoD Expression via MyoD Core Enhancer Transcription. Cell Rep 2017; 18:1996-2006. [PMID: 28228264 DOI: 10.1016/j.celrep.2017.01.078] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2016] [Revised: 12/21/2016] [Accepted: 01/29/2017] [Indexed: 12/22/2022] Open
Abstract
MyoD is a master regulator of myogenesis. Chromatin modifications required to trigger MyoD expression are still poorly described. Here, we demonstrate that the histone demethylase LSD1/KDM1a is recruited on the MyoD core enhancer upon muscle differentiation. Depletion of Lsd1 in myoblasts precludes the removal of H3K9 methylation and the recruitment of RNA polymerase II on the core enhancer, thereby preventing transcription of the non-coding enhancer RNA required for MyoD expression (CEeRNA). Consistently, Lsd1 conditional inactivation in muscle progenitor cells during embryogenesis prevented transcription of the CEeRNA and delayed MyoD expression. Our results demonstrate that LSD1 is required for the timely expression of MyoD in limb buds and identify a new biological function for LSD1 by showing that it can activate RNA polymerase II-dependent transcription of enhancers.
Collapse
Affiliation(s)
- Isabella Scionti
- Institut NeuroMyoGene, CNRS UMR5310, INSERM U1217, Université Lyon1, 46 Allée d'Italie, 69007 Lyon, France; Laboratory of Molecular Biology of the Cell, CNRS UMR5239, Université Lyon 1, ENS Lyon, 46 Allée d'Italie, 69007 Lyon, France
| | - Shinichiro Hayashi
- Biology of the Neuromuscular System, INSERM IMRB-E10 U955, Université Paris-Est, 8 rue du Général Sarrail, 94010 Créteil Cedex, France; Department of Cellular and Molecular Medicine, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan
| | - Sandrine Mouradian
- Institut NeuroMyoGene, CNRS UMR5310, INSERM U1217, Université Lyon1, 46 Allée d'Italie, 69007 Lyon, France; Laboratory of Molecular Biology of the Cell, CNRS UMR5239, Université Lyon 1, ENS Lyon, 46 Allée d'Italie, 69007 Lyon, France
| | - Emmanuelle Girard
- Institut NeuroMyoGene, CNRS UMR5310, INSERM U1217, Université Lyon1, 46 Allée d'Italie, 69007 Lyon, France; Laboratory of Molecular Biology of the Cell, CNRS UMR5239, Université Lyon 1, ENS Lyon, 46 Allée d'Italie, 69007 Lyon, France; Hospices Civils de Lyon, Faculté de Medicine Lyon Est, 3 Quai des Célestins, 69002 Lyon, France
| | - Joana Esteves de Lima
- Biology of the Neuromuscular System, INSERM IMRB-E10 U955, Université Paris-Est, 8 rue du Général Sarrail, 94010 Créteil Cedex, France
| | - Véronique Morel
- Institut NeuroMyoGene, CNRS UMR5310, INSERM U1217, Université Lyon1, 46 Allée d'Italie, 69007 Lyon, France; Laboratory of Molecular Biology of the Cell, CNRS UMR5239, Université Lyon 1, ENS Lyon, 46 Allée d'Italie, 69007 Lyon, France
| | - Thomas Simonet
- Institut NeuroMyoGene, CNRS UMR5310, INSERM U1217, Université Lyon1, 46 Allée d'Italie, 69007 Lyon, France; Laboratory of Molecular Biology of the Cell, CNRS UMR5239, Université Lyon 1, ENS Lyon, 46 Allée d'Italie, 69007 Lyon, France
| | - Maud Wurmser
- Institut Cochin, INSERM U1016, CNRS UMR 8104, Université Paris Descartes, Sorbonne Paris Cité, 22 rue Mechain, 75014 Paris, France
| | - Pascal Maire
- Institut Cochin, INSERM U1016, CNRS UMR 8104, Université Paris Descartes, Sorbonne Paris Cité, 22 rue Mechain, 75014 Paris, France
| | - Katia Ancelin
- Institut NeuroMyoGene, CNRS UMR5310, INSERM U1217, Université Lyon1, 46 Allée d'Italie, 69007 Lyon, France
| | - Eric Metzger
- Klinik für Urologie und Zentrale Klinische Forschung, Klinikum der Universität Freiburg, Breisacherstrasse 66, 79106 Freiburg, Germany; Deutsches Konsortium für Translationale Krebsforschung, Standort Freiburg, 79106 Freiburg, Germany; BIOSS Centre of Biological Signalling Studies, Albert Ludwigs University Freiburg, 79106 Freiburg, Germany
| | - Roland Schüle
- Klinik für Urologie und Zentrale Klinische Forschung, Klinikum der Universität Freiburg, Breisacherstrasse 66, 79106 Freiburg, Germany; Deutsches Konsortium für Translationale Krebsforschung, Standort Freiburg, 79106 Freiburg, Germany; BIOSS Centre of Biological Signalling Studies, Albert Ludwigs University Freiburg, 79106 Freiburg, Germany
| | - Evelyne Goillot
- Institut NeuroMyoGene, CNRS UMR5310, INSERM U1217, Université Lyon1, 46 Allée d'Italie, 69007 Lyon, France; Laboratory of Molecular Biology of the Cell, CNRS UMR5239, Université Lyon 1, ENS Lyon, 46 Allée d'Italie, 69007 Lyon, France.
| | - Frederic Relaix
- Biology of the Neuromuscular System, INSERM IMRB-E10 U955, Université Paris-Est, 8 rue du Général Sarrail, 94010 Créteil Cedex, France
| | - Laurent Schaeffer
- Institut NeuroMyoGene, CNRS UMR5310, INSERM U1217, Université Lyon1, 46 Allée d'Italie, 69007 Lyon, France; Laboratory of Molecular Biology of the Cell, CNRS UMR5239, Université Lyon 1, ENS Lyon, 46 Allée d'Italie, 69007 Lyon, France; Hospices Civils de Lyon, Faculté de Medicine Lyon Est, 3 Quai des Célestins, 69002 Lyon, France.
| |
Collapse
|
2
|
Abstract
Insulin resistance is one of the defining features of type 2 diabetes and the metabolic syndrome and accompanies many other clinical conditions, ranging from obesity to lipodystrophy to glucocorticoid excess. Extraordinary efforts have gone into defining the mechanisms that underlie insulin resistance, with most attention focused on altered signalling as well as mitochondrial and endoplasmic reticulum stress. Here, nuclear mechanisms of insulin resistance, including transcriptional and epigenomic effects, will be discussed. Three levels of control involving transcription factors, transcriptional cofactors, and chromatin-modifying enzymes will be considered. Well-studied examples of the first include PPAR-γ in adipose tissue and the glucocorticoid receptor and FoxO1 in a variety of insulin-sensitive tissues. These proteins work in concert with cofactors such as PGC-1α and CRTC2, and chromatin-modifying enzymes including DNA methyltransferases and histone acetyltransferases, to regulate key genes that promote insulin-stimulated glucose uptake, gluconeogenesis or other pathways that affect systemic insulin action. Furthermore, genetic variation associated with increased risk of type 2 diabetes is often related to altered transcription factor binding, either by affecting the transcription factor itself, or more commonly by changing the binding affinity of a noncoding regulatory region. Finally, several avenues for therapeutic exploitation in the battle against metabolic disease will be discussed, including small-molecule inhibitors and activators of these factors and their related pathways.
Collapse
Affiliation(s)
- E D Rosen
- Division of Endocrinology and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
| |
Collapse
|